Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Iberdomide Enhances Dara Mediated Cytotoxicity through Upregulation of CDC Activity and Elevated NK Cell Mediated ADCC

Peilin Ma, Vinidhra Sridharan, Krista Wollerman, Debjani Dutta, Ram Kumar Singh, Sambuddo Mukherjee, Chad C. Bjorklund, Patrick R Hagner, Michael Amatangelo, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 3289.

https://doi.org/10.1182/blood-2023-189423

Published: 2023

Journal Articles

Preclinical and Translational Biomarker Analyses to Inform Clinical Development of Mezigdomide (CC-92480) in Combination with Dexamethasone and Daratumumab in Multiple Myeloma

Tracy T. Chow, Michael Amatangelo, Peilin Ma, Chad C. Bjorklund, Krista Wollerman, Tiziana Civardi, Phillip Koo, Yue Zhu, Paulo Maciag, Jessica Katz, Aparna Raval, Albert Oriol, Robert Z. Orlowski, Darrell White, Paul G. Richardson, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 3318.

https://doi.org/10.1182/blood-2023-178881

Published: 2023

Journal Articles

Differential Chromatin Organization between t(4;14) and Non-t(4;14) Multiple Myeloma Driven By the Histone Methyltransferase NSD2

Chad C. Bjorklund, Junfei Zhao, Gaurav Jain, Natasha Shtraizent, Maria Ortiz, Sambuddo Mukherjee, Patrick R Hagner, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 3295.

https://doi.org/10.1182/blood-2023-190137

Published: 2023

Journal Articles

Investigation of the Synergistic Combination of a Novel Celmod (CC-99282) and BET Inhibitors in Preclinical DLBCL

Chih-Chao Hsu, Hsiling Chiu, Chad C. Bjorklund, Patrick R Hagner, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 5719.

https://doi.org/10.1182/blood-2023-189191

Published: 2023

Journal Articles

Super-Enhancer Driven Regulation of CKS1B in Multiple Myeloma: Implications in Mediating Response to BET Inhibitor and Celmod Agent Combination

Aarif Ahsan, Ann Polonskaia, Chih-Chao Hsu, Chad C Bjorklund, Maria Ortiz Estevez, Fadi Towfic, Nizar J. Bahlis, Michael Pourdehnad, Erin Flynt, Aarif Ahsan, Anjan Thakurta

Blood (2021) 138 (Supplement 1): 2658.

https://doi.org/10.1182/blood-2021-150641

Published: 2021

Journal Articles

CC-92480 Enhances Cell-Autonomous Cytotoxicity through Blockade of G 2 /M Transition When Combined with Bortezomib/Dexamethasone in Pre-Clinical Multiple Myeloma

Chad C Bjorklund, Michael Amatangelo, Jian Kang, Hsiling Chiu, Archana Mukhopadhyay, Krista Wollerman, Michael Pourdehnad, Patrick Hagner, Anjan Thakurta

Blood (2021) 138 (Supplement 1): 2669.

https://doi.org/10.1182/blood-2021-153907

Published: 2021

Journal Articles

Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma

Chad C Bjorklund, Michael Amatangelo, Hsiling Chiu, Jian Kang, Tiziana Civardi, Jessica Katz, Paulo Maciag, Patrick Hagner, Michael Pourdehnad, Nizar J. Bahlis, Paul G. Richardson, Anjan Thakurta

Blood (2021) 138 (Supplement 1): 1613.

https://doi.org/10.1182/blood-2021-153994

Published: 2021

Journal Articles

ZFP91 Regulates Multiple Myeloma Cell Proliferation through IL-1β Mediated IL-6 Secretion in the Tumor Microenvironment

Danny V Jeyaraju, Ekta Kumari, Michael Amatangelo, Chad C. Bjorklund, Chih-Chao Hsu, Anjan Thakurta

Blood (2019) 134 (Supplement_1): 4406.

https://doi.org/10.1182/blood-2019-129181

Published: 2019

Journal Articles

Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)

Blood (2019) 134 (Supplement_1): 3119.

https://doi.org/10.1182/blood-2019-124298

Published: 2019

Journal Articles

Single Cell Analysis of Acquired Pomalidomide-Resistance in Multiple Myeloma Cell Lines Reveals Distinct Subclonal Cereblon Mutations and Gene Expression Heterogeneity

Sarah Gooding, Chad C. Bjorklund, Michael Amatangelo, Yan Ren, Mathieu Marella, Suzana Couto, Christopher Park, Sneh Lata, Reshma Nibhani, Fadi Towfic, PhD, Udo Oppermann, Karthik Ramasamy, William E. Pierceall, Paresh Vyas, Anjan Thakurta, PhD

Blood (2018) 132 (Supplement 1): 2648.

https://doi.org/10.1182/blood-2018-99-112644

Published: 2018

Journal Articles

Modeling Tumor Microenvironment Interactions of Imid Sensitive and Resistant Cells in 3D Organotypic Culture Models

Aarif Ahsan, PhD, Danny Jeyaraju, Kamlesh Bisht, Patrick R. Hagner, PhD, Chad C. Bjorklund, William E Pierceall, Anjan Thakurta, PhD

Blood (2018) 132 (Supplement 1): 5622.

https://doi.org/10.1182/blood-2018-99-118885

Published: 2018

Journal Articles

Mechanistic Insights of Pomalidomide Activity in Combination with Bortezomib and Dexamethasone in Multiple Myeloma and Immune Cells

Mark Katz, Chad C. Bjorklund, Anjan Thakurta, PhD, Natalya Serbina

Blood (2018) 132 (Supplement 1): 1934.

https://doi.org/10.1182/blood-2018-99-118829

Published: 2018

Journal Articles

Iberdomide (CC-220) Has Synergistic Anti-Tumor and Immunostimulatory Activity Against Multiple Myeloma in Combination with Both Bortezomib and Dexamethasone, or in Combination with Daratumumab in Vitro

Michael Amatangelo, Chad C. Bjorklund, Jian Kang, Ann Polonskaia, Sridevi Viswanatha, Anjan Thakurta, PhD

Blood (2018) 132 (Supplement 1): 1935.

https://doi.org/10.1182/blood-2018-99-113383

Published: 2018

Journal Articles

CC-220 Is a Potent Cereblon Modulating Agent That Displays Anti-Proliferative, Pro-Apoptotic and Immunomodulatory Activity on Sensitive and Resistant Multiple Myeloma Cell Lines

Chad C Bjorklund, PhD, Jian Kang, Ling Lu, Michael Amatangelo, PhD, Hsiling Chiu, Anita K. Gandhi, PhD, Michael Pourdehnad, MD, Anke Klippel, PhD, Anjan Thakurta, PhD

Blood (2016) 128 (22): 1591.

https://doi.org/10.1182/blood.V128.22.1591.1591

Published: 2016

Journal Articles

CC-122 Is a Cereblon Modulating Agent That Is Active in Lenalidomide-Resistant and Lenalidomide/Dexamethasone-Double-Resistant Multiple Myeloma Pre-Clinical Models

Chad C Bjorklund, PhD, Jian Kang, Ling Lu, Michael Amatangelo, PhD, Hsiling Chiu, Patrick Hagner, PhD, Anita K. Gandhi, PhD, Michael Pourdehnad, MD, Anke Klippel, PhD, Anjan Thakurta, PhD

Blood (2016) 128 (22): 1592.

https://doi.org/10.1182/blood.V128.22.1592.1592

Published: 2016

Journal Articles

Resistance to Lenalidomide in Multiple Myeloma Is Associated with a Switch in Gene Expression Profile

Michael D. Amatangelo, PhD, Paola Neri, MD PhD, Maria Ortiz, PhD, Chad C. Bjorklund, Anita K. Gandhi, PhD, Anke Klippel, Nizar J Bahlis, MD, Tom Daniel, Rajesh Chopra, MBBS, PhD, Matthew Trotter, Anjan Thakurta

Blood (2015) 126 (23): 1789.

https://doi.org/10.1182/blood.V126.23.1789.1789

Published: 2015

Journal Articles

Lenalidomide (LEN) and Epstein-Barr Virus (EBV) Reactivation

Melinda Mezo, Chad C. Bjorklund, Lilia Weiss, Neil Minton, John Freeman

Blood (2015) 126 (23): 5372.

https://doi.org/10.1182/blood.V126.23.5372.5372

Published: 2015

Journal Articles

IMiD® Immunomodulatory Agents Promote Apoptosis in Multiple Myeloma Cells through Induction of TRAIL Expression

Michael D. Amatangelo, PhD, Chad C. Bjorklund, Anita K. Gandhi, PhD, Anke Klippel, Tom Daniel, Rajesh Chopra, MBBS, PhD, Matthew Trotter, Anjan Thakurta

Blood (2015) 126 (23): 5355.

https://doi.org/10.1182/blood.V126.23.5355.5355

Published: 2015

Journal Articles

Degradation of Aiolos and Ikaros Followed By Downregulation of c-Myc and then IRF4 Leads to Programmed Cell Death in Myeloma Cells Sensitive to IMiDs ® Immunomodulatory Compounds

Chad C Bjorklund, PhD, Courtney G. Havens, PhD, Patrick R Hagner, PhD, Anita K. Gandhi, PhD, Maria Wang, PhD, Michael D Amatangelo, PhD, Ling Lu, BS, Huisheng Wang, MS, Mike Breider, DVM, PhD DACVP, Yan Ren, MS, Antonia Lopez-Girona, PhD, Anjan Thakurta, PhD, Anke Klippel, PhD, Rajesh Chopra, MD PhD

Blood (2014) 124 (21): 4700.

https://doi.org/10.1182/blood.V124.21.4700.4700

Published: 2014

Journal Articles

CC-122 Has Potent Anti-Lymphoma Activity through Destruction of the Aiolos and Ikaros Transcription Factors and Induction of Interferon Response Pathways

Patrick Hagner, PhD, Maria Wang, PhD, Suzana Couto, PhD, Mike Breider, DVM, PhD DACVP, Celia Fontanillo, PhD, Matthew Trotter, PhD, Chad C Bjorklund, PhD, Courtney G. Havens, PhD, Heather K Raymon, PhD, Rama Krishna Narla, PhD, Leo Barnes, PhD, Michelle Waldman, MS, Tom Daniel, MD, Anke Klippel, PhD, Michael Pourdehnad, MD, Anjan Thakurta, PhD, Rajesh Chopra, MD, PhD, Anita K. Gandhi, PhD

Blood (2014) 124 (21): 3035.

https://doi.org/10.1182/blood.V124.21.3035.3035

Published: 2014

NARROW

Iberdomide Enhances Dara Mediated Cytotoxicity through Upregulation of CDC Activity and Elevated NK Cell Mediated ADCC

Preclinical and Translational Biomarker Analyses to Inform Clinical Development of Mezigdomide (CC-92480) in Combination with Dexamethasone and Daratumumab in Multiple Myeloma

Differential Chromatin Organization between t(4;14) and Non-t(4;14) Multiple Myeloma Driven By the Histone Methyltransferase NSD2

Investigation of the Synergistic Combination of a Novel Celmod (CC-99282) and BET Inhibitors in Preclinical DLBCL

Super-Enhancer Driven Regulation of CKS1B in Multiple Myeloma: Implications in Mediating Response to BET Inhibitor and Celmod Agent Combination

CC-92480 Enhances Cell-Autonomous Cytotoxicity through Blockade of G 2 /M Transition When Combined with Bortezomib/Dexamethasone in Pre-Clinical Multiple Myeloma

Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma

ZFP91 Regulates Multiple Myeloma Cell Proliferation through IL-1β Mediated IL-6 Secretion in the Tumor Microenvironment

Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)

Single Cell Analysis of Acquired Pomalidomide-Resistance in Multiple Myeloma Cell Lines Reveals Distinct Subclonal Cereblon Mutations and Gene Expression Heterogeneity

Modeling Tumor Microenvironment Interactions of Imid Sensitive and Resistant Cells in 3D Organotypic Culture Models

Mechanistic Insights of Pomalidomide Activity in Combination with Bortezomib and Dexamethasone in Multiple Myeloma and Immune Cells

Iberdomide (CC-220) Has Synergistic Anti-Tumor and Immunostimulatory Activity Against Multiple Myeloma in Combination with Both Bortezomib and Dexamethasone, or in Combination with Daratumumab in Vitro

CC-220 Is a Potent Cereblon Modulating Agent That Displays Anti-Proliferative, Pro-Apoptotic and Immunomodulatory Activity on Sensitive and Resistant Multiple Myeloma Cell Lines

CC-122 Is a Cereblon Modulating Agent That Is Active in Lenalidomide-Resistant and Lenalidomide/Dexamethasone-Double-Resistant Multiple Myeloma Pre-Clinical Models

Resistance to Lenalidomide in Multiple Myeloma Is Associated with a Switch in Gene Expression Profile

Lenalidomide (LEN) and Epstein-Barr Virus (EBV) Reactivation

IMiD® Immunomodulatory Agents Promote Apoptosis in Multiple Myeloma Cells through Induction of TRAIL Expression

Degradation of Aiolos and Ikaros Followed By Downregulation of c-Myc and then IRF4 Leads to Programmed Cell Death in Myeloma Cells Sensitive to IMiDs ® Immunomodulatory Compounds

CC-122 Has Potent Anti-Lymphoma Activity through Destruction of the Aiolos and Ikaros Transcription Factors and Induction of Interferon Response Pathways

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only